The global hepatitis C market size accounted for USD 71.86 billion in 2024, grew to USD 82.06 billion in 2025 and is expected to be worth around USD 271.11 billion by 2034, registering a CAGR of 14.2% between 2024 and 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Hepatitis C Market
5.1. COVID-19 Landscape: Hepatitis C Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Hepatitis C Market, By Drug Class
8.1. Hepatitis C Market, by Drug Class, 2024-2034
8.1.1. HCV Protease Inhibitors
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. HCV Polymerase Inhibitors
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. HCV NSSA Inhibitors
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Combination Therapy
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Interferon and Antiviral
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Peginterferon alfa 2a
8.1.6.1. Market Revenue and Forecast (2021-2034)
8.1.7. Peginterferon alfa 2b
8.1.7.1. Market Revenue and Forecast (2021-2034)
8.1.8. Ribavirin
8.1.8.1. Market Revenue and Forecast (2021-2034)
8.1.9. Others
8.1.9.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Hepatitis C Market, By Distribution Channel
9.1. Hepatitis C Market, by Distribution Channel, 2024-2034
9.1.1. Hospital & Retail Pharmacies
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Online Pharmacies
9.1.2.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Hepatitis C Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.1.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.2.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
Chapter 11. Company Profiles
11.1. Bristol-Myers Squibb Company
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Gilead Sciences, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Abbvie
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Kadmon Holdings Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. F. Hoffmon La Roche Ltd.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. GlaxoSmithKline
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. J & J
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Lupin Pharmaceuticals, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Merck & Co., Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Teva Pharmaceuticals
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample